Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2022-06-09 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
股东大会议事规则（2022年6月9日）
Governance Information Classification · 95% confidence The document is titled '股东大会议事规则' which translates to 'Rules of Procedure for the Shareholders' General Meeting' of 康芝药业股份有限公司. It extensively details the procedures, powers, notification requirements, proposal handling, voting rules, and other governance aspects related to shareholders' meetings. It does not contain financial statements, audit opinions, or earnings data. Instead, it focuses on the governance and procedural framework for conducting shareholder meetings. This aligns with the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy (15,000 characters) and is not a mere announcement or notice but a comprehensive governance document. Therefore, the appropriate classification is CGR with high confidence.
2022-06-09 Chinese
《公司章程》（2022年6月9日）
Governance Information Classification · 100% confidence The document is the company bylaws (公司章程) of 康芝药业股份有限公司, detailing the company's organizational structure, shareholder rights, board and management roles, financial accounting, and other governance matters. It is a comprehensive internal governance document, not a financial report, announcement, or meeting material. It does not contain financial statements, earnings data, voting results, or call transcripts. It is a governance information document outlining the company's internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is not a brief announcement or regulatory filing.
2022-06-09 Chinese
关于修改监事会议事规则修订对照表
Regulatory Filings Classification · 95% confidence The document is a formal announcement from 康芝药业股份有限公司 regarding the revision of the Supervisory Board Meeting Rules (监事会议事规则). It references relevant laws and regulations, details specific amendments to the rules, and states that the revised rules will be submitted to the 2021 Annual General Meeting for approval. The document is relatively short (3332 characters) and serves as a notification of the rule changes rather than the full governance document itself. It does not contain financial data, audit results, or detailed management reports. The content focuses on governance procedures and internal supervisory rules, which aligns with governance information. However, since it is an announcement of the revision and submission for approval rather than the full governance report or charter, and given the document length and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about governance changes.
2022-06-09 Chinese
关于修改公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's articles of association (公司章程) and related governance rules. It includes specific clauses about shareholder rights, board responsibilities, meeting procedures, and other corporate governance matters. The content is focused on the internal rules and governance structure of the company rather than financial results, audit opinions, or shareholder meeting results. There is no indication that this is a report of voting results, a financial report, or a call transcript. The document is not a proxy solicitation or remuneration report either. Given the extensive focus on governance rules, board and shareholder meeting procedures, and company bylaws, the document best fits the category of Governance Information (CGR).
2022-06-09 Chinese
董事会议事规则 （2022年6月9日）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors' of 康芝药业股份有限公司. It details the structure, powers, responsibilities, and procedural rules of the company's board of directors. It references relevant laws and regulations governing board operations and governance. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is over 6000 characters, indicating it is a full document, not a brief announcement or certification.
2022-06-09 Chinese
第五届监事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. It details the decisions made during the 20th meeting of the 5th Supervisory Board, including approval of the appointment of the 2022 audit firm, authorization for the board to handle a simplified stock issuance, and amendments to the company charter and meeting rules. The document is a formal announcement of board/management decisions and governance matters, not a full report or financial statement. It does not contain financial data or detailed financial analysis, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive meeting resolutions. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (2115 characters), consistent with an announcement rather than a full report.
2022-06-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.